Nahid Moradi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nahid Moradi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ali Asadian
Department of Anesthesiology, School of Paramedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Ali Shirbacheh
Urgences, Centre Hospitalier de l’Agglomération de Nevers, Nevers, France
1 shared publication - Alireza Amanollahi
Trauma and Injury Research Center Iran University of Medical Sciences Tehran Iran
1 shared publication - Anna Ghorbani Doshantapeh
Department of Hematology-Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Farshad Gharebakhshi
Department of Radiology, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Farzaneh Barkhordari Ahmadi
Department of Anesthesiology, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publication
Latest Publications
- Open Access
Saccharomyces boulardii as Adjunctive Therapy in Helicobacter pylori Eradication: A Randomized, Placebo-Controlled Trial
Background: Helicobacter pylori (H. pylori) infection remains highly prevalent in Iran, where high antibiotic resistance can limit eradication efficacy. Saccharomyces boulardii (S. boulardii) may improve eradication and treatment tolerability, although evidence remains inconsistent. This trial evaluated adjunctive S. boulardii in a high-prevalence, high-resistance setting. Methods: In this randomized, single-blind, placebo-controlled trial, 218 H. pylori–positive adults received 14 days of PPI, bismuth, amoxicillin, and clarithromycin (P-BAC) plus either S. boulardii (250 mg twice daily) or placebo. The primary outcome was H. pylori eradication assessed 30 days after treatment by stool antigen testing, analyzed by intention-to-treat (ITT) and per-protocol (PP) principles. Treatment-related adverse events were secondary outcomes. Trial registration: Iranian Registry of Clinical Trials, IRCT20230827059280N1. Results: In the PP analysis, eradication was lower with S. boulardii than placebo (65.0% vs. 76.5%; RR = 0.849, 95% CI: 0.709–1.018), with a similar pattern in the ITT analysis (59.6% vs. 68.8%; RR = 0.867, 95% CI: 0.710–1.058). Neither analysis showed a statistically significant difference. Overall adverse events were significantly less frequent with S. boulardii (44.0% vs. 68.4%; RR = 0.644, 95% CI: 0.497–0.834; P < 0.001), with lower rates of bloating (4.0% vs. 23.5%; adjusted P < 0.001) and epigastric pain (4.0% vs. 14.3%; adjusted P = 0.041). Conclusion: Adjunctive S. boulardii did not significantly improve H. pylori eradication with 14-day P-BAC therapy. However, it significantly reduced adverse events, particularly bloating and epigastric pain. Further multicenter trials incorporating individualized susceptibility testing are warranted.
Open AccessSaccharomyces boulardii as Adjunctive Therapy in Helicobacter pylori Eradication: A Randomized, Placebo-Controlled Trial
Background: Helicobacter pylori (H. pylori) infection remains highly prevalent in Iran, where high antibiotic resistance can limit eradication efficacy. Saccharomyces boulardii (S. boulardii) may improve eradication and treatment tolerability, although evidence remains inconsistent. This trial evaluated adjunctive S. boulardii in a high-prevalence, high-resistance setting. Methods: In this randomized, single-blind, placebo-controlled trial, 218 H. pylori–positive adults received 14 days of PPI, bismuth, amoxicillin, and clarithromycin (P-BAC) plus either S. boulardii (250 mg twice daily) or placebo. The primary outcome was H. pylori eradication assessed 30 days after treatment by stool antigen testing, analyzed by intention-to-treat (ITT) and per-protocol (PP) principles. Treatment-related adverse events were secondary outcomes. Trial registration: Iranian Registry of Clinical Trials, IRCT20230827059280N1. Results: In the PP analysis, eradication was lower with S. boulardii than placebo (65.0% vs. 76.5%; RR = 0.849, 95% CI: 0.709–1.018), with a similar pattern in the ITT analysis (59.6% vs. 68.8%; RR = 0.867, 95% CI: 0.710–1.058). Neither analysis showed a statistically significant difference. Overall adverse events were significantly less frequent with S. boulardii (44.0% vs. 68.4%; RR = 0.644, 95% CI: 0.497–0.834; P < 0.001), with lower rates of bloating (4.0% vs. 23.5%; adjusted P < 0.001) and epigastric pain (4.0% vs. 14.3%; adjusted P = 0.041). Conclusion: Adjunctive S. boulardii did not significantly improve H. pylori eradication with 14-day P-BAC therapy. However, it significantly reduced adverse events, particularly bloating and epigastric pain. Further multicenter trials incorporating individualized susceptibility testing are warranted.
- Open Access
- 2 November 2024
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14 (1) , e12712
The effect of body mass index on estimated glomerular filtration rate in patients with IgA nephropathy; a systematic review and meta-analysis of the cohort studies
Introduction: The study is motivated by the growing concern surrounding chronic kidney disease worldwide and the need for early identification and effective management to slow or prevent kidney disease progression. To achieve this goal, we evaluated the correlation between body mass index (BMI) and estimated glomerular filtration rate (eGFR) in patients with IgA nephropathy through a systematic review and meta-analysis. Materials and Methods: The data were acquired after conducting a comprehensive exploration of the international databases of PubMed, Scopus, Web of Science, Cochrane, and the Google Scholar search engine until June 2024. The study heterogeneity was evaluated utilizing the I2 index. The data were scrutinized employing STATA 14, and a P value < 0.05 was considered significant. Results: Seven studies with a sample size of 1354 normal BMI people and 1020 obese or overweight patients were included in this meta-analysis. Based on the findings of the weighted mean difference (WMD), individuals who are overweight or obese had a lower eGFR (WMD = -7.34 [CI; -9.62, -5.05], P<0.001). Conclusion: The results demonstrated that the eGFR was significantly lower in obese or overweight people compared to individuals with normal BMI; therefore, we conclude that being overweight or obese may hurt kidney function. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023417633) and Research Registry (UIN: reviewregistry1665) websites.
- 2 November 2024
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14 (1) , e12712
Open AccessThe effect of body mass index on estimated glomerular filtration rate in patients with IgA nephropathy; a systematic review and meta-analysis of the cohort studies
Introduction: The study is motivated by the growing concern surrounding chronic kidney disease worldwide and the need for early identification and effective management to slow or prevent kidney disease progression. To achieve this goal, we evaluated the correlation between body mass index (BMI) and estimated glomerular filtration rate (eGFR) in patients with IgA nephropathy through a systematic review and meta-analysis. Materials and Methods: The data were acquired after conducting a comprehensive exploration of the international databases of PubMed, Scopus, Web of Science, Cochrane, and the Google Scholar search engine until June 2024. The study heterogeneity was evaluated utilizing the I2 index. The data were scrutinized employing STATA 14, and a P value < 0.05 was considered significant. Results: Seven studies with a sample size of 1354 normal BMI people and 1020 obese or overweight patients were included in this meta-analysis. Based on the findings of the weighted mean difference (WMD), individuals who are overweight or obese had a lower eGFR (WMD = -7.34 [CI; -9.62, -5.05], P<0.001). Conclusion: The results demonstrated that the eGFR was significantly lower in obese or overweight people compared to individuals with normal BMI; therefore, we conclude that being overweight or obese may hurt kidney function. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023417633) and Research Registry (UIN: reviewregistry1665) websites.
- Open Access
- 13 January 2024
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 13 (2) , e11659
Renal insufficiency in breast cancer patients; a review study
The latest statistics and estimations indicated that breast cancer occurs in one-fourth of women worldwide and is responsible for one in six cancer deaths among women. A bilateral relationship seems to exist between breast cancer pathophysiology and kidney failure. Consideration should be given to this relationship when selecting a treatment protocol. This paper reviews the association between these two factors in breast cancer patients. There are many aspects to consider in the association between breast cancer and renal insufficiency. A breast cancer patient with normal kidney function is at risk of developing kidney failure due to paraneoplastic syndromes, hypercalcemia, and in rare cases, tumor lysis syndrome (TLS). In defining the optimal treatment protocol for each breast cancer patient, clinicians should consider the patient’s basal glomerular filtration rate (GFR). Frequent renal clearance monitoring and taking immediate action at the time GFR begins to decrease will lower the rate of kidney failure in breast cancer patients. Lastly, patients with chronic kidney disease who are recently diagnosed with breast cancer may have higher morbidity and mortality compared to breast cancer patients with normal GFR. Further investigation is needed to lower morbidity and mortality in such patients.
- 13 January 2024
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 13 (2) , e11659
Open AccessRenal insufficiency in breast cancer patients; a review study
The latest statistics and estimations indicated that breast cancer occurs in one-fourth of women worldwide and is responsible for one in six cancer deaths among women. A bilateral relationship seems to exist between breast cancer pathophysiology and kidney failure. Consideration should be given to this relationship when selecting a treatment protocol. This paper reviews the association between these two factors in breast cancer patients. There are many aspects to consider in the association between breast cancer and renal insufficiency. A breast cancer patient with normal kidney function is at risk of developing kidney failure due to paraneoplastic syndromes, hypercalcemia, and in rare cases, tumor lysis syndrome (TLS). In defining the optimal treatment protocol for each breast cancer patient, clinicians should consider the patient’s basal glomerular filtration rate (GFR). Frequent renal clearance monitoring and taking immediate action at the time GFR begins to decrease will lower the rate of kidney failure in breast cancer patients. Lastly, patients with chronic kidney disease who are recently diagnosed with breast cancer may have higher morbidity and mortality compared to breast cancer patients with normal GFR. Further investigation is needed to lower morbidity and mortality in such patients.
- Open Access
- 1 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Endocrinology
- Vol. 10 (1) , e25174
Renal manifestations of hemochromatosis; an update to recent findings
Hemochromatosis is a genetic disorder that results in excessive iron absorption, followed by iron overload in various organs including the kidneys. IgA nephropathy, on the other hand, is the immunoglobulin A (IgA) deposition in the glomeruli mesangium. Hemochromatosis-associated IgA nephropathy is a condition described as both hemochromatosis and IgA nephropathy in an individual. Recently, there has been growing evidence suggesting a potential association between IgA nephropathy and hemochromatosis. Previous studies have indicated that individuals with hemochromatosis may have an increased risk of developing IgA nephropathy. Some studies suggest a higher prevalence of hemochromatosis-associated gene mutations particularly HFE gene mutations, in IgA nephropathy patients. These gene mutations may affect iron metabolism and contribute to the development of both conditions. Excessive iron in the kidney may also be associated with increasing inflammatory response and IgA deposition in the glomeruli. Treatment options for hemochromatosis-associated IgA include corticosteroids, RAS blockade, immunosuppressive agents, and supportive care for chronic kidney disease.
- 1 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Endocrinology
- Vol. 10 (1) , e25174
Open AccessRenal manifestations of hemochromatosis; an update to recent findings
Hemochromatosis is a genetic disorder that results in excessive iron absorption, followed by iron overload in various organs including the kidneys. IgA nephropathy, on the other hand, is the immunoglobulin A (IgA) deposition in the glomeruli mesangium. Hemochromatosis-associated IgA nephropathy is a condition described as both hemochromatosis and IgA nephropathy in an individual. Recently, there has been growing evidence suggesting a potential association between IgA nephropathy and hemochromatosis. Previous studies have indicated that individuals with hemochromatosis may have an increased risk of developing IgA nephropathy. Some studies suggest a higher prevalence of hemochromatosis-associated gene mutations particularly HFE gene mutations, in IgA nephropathy patients. These gene mutations may affect iron metabolism and contribute to the development of both conditions. Excessive iron in the kidney may also be associated with increasing inflammatory response and IgA deposition in the glomeruli. Treatment options for hemochromatosis-associated IgA include corticosteroids, RAS blockade, immunosuppressive agents, and supportive care for chronic kidney disease.
- Open Access
- 1 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Endocrinology
- Vol. 10 (1) , e25154
Breast cancer in individuals with type 2 diabetes; a mini-review to the recent concepts
Introduction: Pieces of evidence indicate a relationship between breast cancer and type 2 diabetes (T2D) which is a potential risk factor for breast cancer development and progression. Hyperinsulinemia, insulin resistance, chronic inflammation, inflammatory cytokines, and hormonal factors are possible explanations for this association. T2D may also affect the breast cancer treatment course. Neoplastic cells are more chemo-resistant, and chemotherapy adverse effects are more prominent in patients with diabetes and breast cancer at the same time. Diabetic nephropathy is one of the T2D complications that should be considered prior to choosing a therapeutic protocol for breast cancer patients. Hence, collaboration between oncologists, endocrinologists, and nephrologists is essential to provide comprehensive care for T2D and breast cancer patients.
- 1 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Endocrinology
- Vol. 10 (1) , e25154
Open AccessBreast cancer in individuals with type 2 diabetes; a mini-review to the recent concepts
Introduction: Pieces of evidence indicate a relationship between breast cancer and type 2 diabetes (T2D) which is a potential risk factor for breast cancer development and progression. Hyperinsulinemia, insulin resistance, chronic inflammation, inflammatory cytokines, and hormonal factors are possible explanations for this association. T2D may also affect the breast cancer treatment course. Neoplastic cells are more chemo-resistant, and chemotherapy adverse effects are more prominent in patients with diabetes and breast cancer at the same time. Diabetic nephropathy is one of the T2D complications that should be considered prior to choosing a therapeutic protocol for breast cancer patients. Hence, collaboration between oncologists, endocrinologists, and nephrologists is essential to provide comprehensive care for T2D and breast cancer patients.
- Open Access
- 1 January 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Endocrinology
- Vol. 9 (1) , e25137
An ecological study of the incidence and mortality rates of pancreatic cancer in 2020: exploring gender disparities worldwide
Introduction: Pancreatic cancer is a highly mortal disease that used to be rare but its incidence rate has increased in the last few decades. Despite declining overall cancer incidence and mortality rates in developed countries, pancreatic cancer tends to increase in both incidence and mortality. Previous studies showed a male predominance in pancreatic cancer in patients older than 35. However, considering the sudden rise in incidence in young females, a new survey is crucial to address the current pattern of pancreatic cancer distribution between males and females. Hormonal factors may play a role in the pathogenesis of pancreatic cancer. Objectives: This study aimed to evaluate the role of gender differences in mortality and incidence of pancreatic cancer in an ecological study based on data extracted from the GLOBOCAN project in 2020. Patients and Methods: An ecological study was carried out to assess gender disparity in pancreatic cancer incidence and mortality rates. The data used in the study were obtained from the Global Cancer (GLOBOCAN) project of the World Health Organization (WHO) in 2020 (https://gco.iarc.fr/). Results: The pancreatic cancer mortality rate worldwide (2020) was estimated at 466,003 cases, encompassing 246,840 cases (52.96%) among males and 219,163 cases (47.04%) among females. The study found that although there were differences in the mean pancreatic cancer incidence and mortality rates between males and females when measured by indicators such as number, ASR, and crude rate, these differences were not statistically significant. Conclusion: In conclusion, the pancreatic cancer incidence and mortality rate is increasing worldwide. In spite of the fact that men die from pancreatic cancer at a higher rate than women, there is no statistically significant difference between the two. Registration: The study protocol was registered on the Research Registry website with the unique identification number (UIN) researchregistry9598.
- 1 January 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Endocrinology
- Vol. 9 (1) , e25137
Open AccessAn ecological study of the incidence and mortality rates of pancreatic cancer in 2020: exploring gender disparities worldwide
Introduction: Pancreatic cancer is a highly mortal disease that used to be rare but its incidence rate has increased in the last few decades. Despite declining overall cancer incidence and mortality rates in developed countries, pancreatic cancer tends to increase in both incidence and mortality. Previous studies showed a male predominance in pancreatic cancer in patients older than 35. However, considering the sudden rise in incidence in young females, a new survey is crucial to address the current pattern of pancreatic cancer distribution between males and females. Hormonal factors may play a role in the pathogenesis of pancreatic cancer. Objectives: This study aimed to evaluate the role of gender differences in mortality and incidence of pancreatic cancer in an ecological study based on data extracted from the GLOBOCAN project in 2020. Patients and Methods: An ecological study was carried out to assess gender disparity in pancreatic cancer incidence and mortality rates. The data used in the study were obtained from the Global Cancer (GLOBOCAN) project of the World Health Organization (WHO) in 2020 (https://gco.iarc.fr/). Results: The pancreatic cancer mortality rate worldwide (2020) was estimated at 466,003 cases, encompassing 246,840 cases (52.96%) among males and 219,163 cases (47.04%) among females. The study found that although there were differences in the mean pancreatic cancer incidence and mortality rates between males and females when measured by indicators such as number, ASR, and crude rate, these differences were not statistically significant. Conclusion: In conclusion, the pancreatic cancer incidence and mortality rate is increasing worldwide. In spite of the fact that men die from pancreatic cancer at a higher rate than women, there is no statistically significant difference between the two. Registration: The study protocol was registered on the Research Registry website with the unique identification number (UIN) researchregistry9598.